Vollständiger Abstract
Worum geht es in dieser Arbeit?
Immunohistochemistry (IHC) of ER, PR, HER2, and Ki67 are established prognostic and predictive markers in breast cancer. Gene expression assays such as PAM50 and Oncotype DX are increasingly used for molecular subtyping and recurrence risk calculation. The APIS Breast Cancer Subtyping Kit (BCSK) quantitatively measures the mRNA expression of these markers (ER, PR, HER2, and Ki67) and includes a novel four-gene BCSK Proliferation Signature (PS) designed for subtype classification and risk stratification. This exploratory retrospective cohort study compares the BCSK with established molecular assays in an age-stratified cohort. We aimed to compare BCSK subtype classification in distinguishing Luminal A versus Luminal B subtypes with IHC and with PAM50. We have also aimed to assess correlations between the BCSK PS and the Oncotype DX Recurrence Score (RS) as well as the PAM50 Risk of Recurrence (ROR) score in patients stratified by age (
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Till Wallrabenstein, Elena Diana Chiru, Martina Sonderegger, Simone Muenst, Christian Kurzeder, Marcus Vetter
- Quelle
- Current Issues in Molecular Biology
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 1467-3045
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Till Wallrabenstein, Elena Diana Chiru, Martina Sonderegger, Simone Muenst, Christian Kurzeder, Marcus Vetter (2026). Comparison of a Novel MRNA-Based Breast Cancer Subtyping Assay with PAM50 and Oncotype DX in Estrogen Receptor-Positive/HER2-Negative Breast Cancer: An Exploratory Age-Stratified Retrospective Cohort Study. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb48090886
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1